For all press and media enquiries please contact mediarelations@chiesi.com
Positive first-half performance underpins full-year 2025 outlook; the Group highlights resilience amid the macro-economic headwinds while advancing its Patients-Planet-People-Prosperity strategy HIGHLIGHTS € 1.86 billion sales revenues, 13.2% organic growth at constant exchange rates (CER). EBITDA…
Nazareth, Israel and Parma, Italy, June 05, 2025 – Elgan Pharma Ltd. and Chiesi Farmaceutici S.p.A today announced the dosing of the first participating infants in FIT-PIV, a Phase 3 clinical study to assess the efficacy and safety of ELGN-2112, an investigational drug candidate for treatment of…
HIGHLIGHTS €3.4 billion revenues, up 13% at constant exchange rates (CER) compared to 2023 Record R&D investment of €829 million (24.3% of revenues) Profitability close to 30% for the fifth consecutive year Air franchise: revenues of €1.8 billion, a growth of 7.2%% (CER). Fastest growing company…
The project is part of the Group’s industrial plan to support its global growth The site will specialize in the production of sterile biological products, DPI and carbon minimal inhalers for the treatment of respiratory diseases, with a primary focus on the latter The redevelopment of the facility…
Chiesi Group appoints Roch Doliveux, Paolo Pucci, and Daphne Quimi to further enhance Board capabilities and internationalize leadership These senior business leaders bring diverse expertise and international experience, strengthening governance and international best practices, whilst supporting…
Chiesi Group is making a strategic investment of €400 to establish its new Biotech Center of Excellence in Parma. The Center is designed to integrate the entire supply chain, enhancing innovation and production, while its seamless research-production integration will accelerate product development…
Highlights from Chiesi Group’s 2023 financial report: Sales increased to over €3 billion, up 10% compared to 2022 (+12% @CER), driven by the Rare business unit growth (65% @CER), and steady growth of all products in all its Regions 24% of 2023 sales were devoted to R&D to create innovative…
The new agreement covers the three-year period 2024-2026 and applies to over 2,200 people from Chiesi Farmaceutici and Chiesi Italia employed under Italian law. An innovative labor agreement has been created to include many new elements and improvements related to Inclusivity, Equity, and…
Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi, a fundamental pillar of the company who shaped its history alongside his brother Alberto. Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate Research and Development…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
